The efficacy of human atrial natriuretic peptide in patients with renal dysfunction undergoing cardiac surgery

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

Who Took Part

The abstract describes 18 patients taking part.

The subjects were prospectively assigned to 2 groups: an h-ANP-treated group (Group H, n = 10) and a non-h-ANP-treated group (Group N, n = 8).

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

The timeline in the abstract includes 5 days.

At the beginning of surgery, h-ANP administration was initiated and continued for 5 days or more.

The primary end point included the serum Cr level and creatinine clearance (Ccr).

What Was Measured

Topics PubMed links to this paper include Acetylglucosaminidase, Atrial Natriuretic Factor, Biomarkers, Blood Urea Nitrogen, Cardiac Surgical Procedures, Cardiopulmonary Bypass and Creatinine.

What This Means in Plain Language

The paper is a randomized study of ANP (Atrial Natriuretic Peptide) in 18 patients over 5 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia), a journal based in Japan.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.